US 12,215,386 B2
Blood biomarkers for appendicitis and diagnostics methods using biomarkers
Lakhmir S. Chawla, McLean, VA (US); and Timothy A. McCaffrey, Silver Spring, MD (US)
Assigned to The George Washington University, Washington, DC (US)
Filed by The George Washington University, Washington, DC (US)
Filed on Jun. 9, 2021, as Appl. No. 17/343,285.
Application 17/343,285 is a continuation of application No. 15/521,224, granted, now 11,066,706, previously published as PCT/US2015/057009, filed on Oct. 22, 2015.
Claims priority of provisional application 62/067,414, filed on Oct. 22, 2014.
Prior Publication US 2022/0090199 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); G01N 33/566 (2006.01); G01N 33/84 (2006.01)
CPC C12Q 1/6883 (2013.01) [G01N 33/6893 (2013.01); C12Q 2600/158 (2013.01); G01N 33/566 (2013.01); G01N 33/84 (2013.01); G01N 2500/04 (2013.01); G01N 2800/06 (2013.01)] 17 Claims
 
1. A method of treating a human subject diagnosed with appendicitis comprising administering an antibiotic to the subject, removing the appendix of the subject, or a combination thereof, wherein the human subject is diagnosed by a method comprising:
obtaining a biological sample from said subject;
detecting expression levels of at least three or more biomarkers in the biological sample selected from the group consisting of Chemokine C-X-C receptor 1, Interleukin 8 receptor β, Fe frag of IgG receptor IIIb (CD16b), MHC class II DR beta 5, Leukocyte IgG-like receptor A3, Defensin alpha 1, Defensin alpha 1B, Defensin alpha 3, 18S ribosomal RNA, CDC14A, 28S ribosomal RNA, 60S acidic ribosomal protein P1, 40S ribosomal protein S26, Ribosomal protein L23, Ribosomal protein L37a, Ribosomal protein S28, Alkaline phosphatase, Carbonic anhydrase IV, Neuroblastoma breakpoint family 10, Ninjurin 1, Prokineticin 2, Superoxide dismutase 2, LOC100129902, LOC100131205, LOC100131905, LOC100132291, LOC100132394, LOC100132742, LOC100134364, LOC391370, LOC646785, LOC644191 and C5orf32; and
diagnosing the subject with appendicitis when at least three or more of said biomarkers are differentially expressed compared to the expression levels of said biomarkers in a group of human subjects not suffering from appendicitis.